Blood bank for studying atrial fibrillation and stroke genes
Collects blood from people with atrial fibrillation or stroke to study genetic causes.
Key facts
- Who runs it
- Hospices Civils de Lyon
- Where
- Bourg-en-Bresse, Bron, Pierre-Bénite, and Villeurbanne, FranceSee the 5 sites
- Trial code
- Registry title
- Biological Bank for Atrial Fibrillation and Stroke
- Status
- Recruiting
- People taking part
- 1,000 people, planned
- Started
- 23 Apr 2018
- Expected to end
- 23 Apr 2033
- Type of study
- Observational, 5 groups
- Treatments tested
- Blood taken
- Record updated
- 17 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with atrial fibrillation, with or without stroke, and for some older and younger comparison groups. Blood samples are taken for a biological bank.
- Age
- 18 years and older. One group is over 80. One group had a stroke or transient ischemic attack before age 50.
- Sex
- Men and women can join.
- Disease stage
- Several groups: atrial fibrillation history; atrial fibrillation with a planned heart rhythm test or ablation; atrial fibrillation or atrial tachycardia with a stroke history; people over 80 with normal rhythm; cryptogenic stroke or transient ischemic attack before age 50 without atrial fibrillation.
Main reasons for not taking part
- Did not sign consent
- Pregnant women (for the group with a planned heart test or ablation)
- No atrial fibrillation history (for the atrial fibrillation groups)
- No stroke history (for the stroke group)
- For the over-80 group: atrial fibrillation, stroke or transient ischemic attack history, or heart disease other than high blood pressure and valve problems
The registry criteria, word for word
Show all 11 criteriaShow less
Other criteria
- Group 1a
- Inclusion Criteria :; AF history
- Exclusion Criteria :; No AF history; patient who didn't signed consent; Group 1b
- Inclusion Criteria :; AF history; Scheduled electrophysiological exploration or AF ablation
- Exclusion Criteria :; No AF history; pregnant women; patient who didn't signed consent; Group 1c
- Inclusion Criteria :; AF/AT history; Stroke history
- Exclusion Criteria :; No Stroke history; patient who didn't signed consent; Group 2
- Inclusion Criteria :; patient over 80; ECG: sinusal rhythm; TTE : no left atrial dilatation
- Exclusion Criteria :; atrial fibrillation history; TTE : Left atria >25cm², > 34m/m2), FEVG < 50%; ECG : QRS > 90 ms; cardiac pathologies (excepted hypertension and valvulopathies); History of stroke and transient ischemic attack; patient who didn't signed consent; Group 3
- Inclusion Criteria :; cryptogenic stroke or transient ischemic attack history before 50 yo; No AF history
- Exclusion Criteria :; AF history; stroke or transient ischemic attack over 50 yo; patient who didn't signed consent
Where in France
- Service neurologie Centre hospitalier FleyriatBourg-en-Bresse, FranceContact: Frédéric PHILIPPEAU, PHTaking people
- Service d'urgences Neurovasculaires - service de neurologie vasculaire , Hôpital Pierre WertheimerBron, FranceContact: Laura MECHTOUFF, PHTaking people
- Service de rythmologie, hôpital cardiologique Louis PradelBron, FranceContact: Philippe CHEVALIER, PU-PHTaking people
- Service de médecine gériatrique Centre hospitalier Lyon Sud, Groupement hospitalier SudPierre-Bénite, FranceContact: Thomas GILBERT, DrTaking people
- Hôpital des CharpennesVilleurbanne, FranceContact: Pierre Krolak-Salmon, PU,PHTaking people
About the trial
What the trial wants to find out
Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in clinical practice. This arrhythmia is responsible for 15% of strokes and more than 30% of strokes on people over 65 years.
Read full original descriptionShow less
According to studies, 30 to 40% of isolated atrial fibrillations could be familial. Atrial fibrillation has significant genetic heterogeneity. About 40 genes have been identified as potentially involved. Studies have identified genes common to the risk of atrial fibrillation and stroke. Despite the pathophysiology of atrial fibrillation has been intensively and extensively studied for almost a century, there are still many questions. The pathophysiology is not sufficiently understood to allow finding more effective therapies. It is necessary to identify genetic determinants and thus potentially new pharmacological targets more adapted.
The establishment of a biological database will test hypotheses concerning the genetic origin and thromboembolic process of atrial fibrillation and associated stroke.
The 5 groups in the trial
- Group 1a
Patient with atrial fibrillation and without stroke history.
Treatment: Blood taken
- Group 1b
Patient with atrial fibrillation with scheduled electrophysiology exploration or ablation.
Treatment: Blood taken
- Group 1c
Patient with atrial fibrillation and with stroke history.
Treatment: Blood taken
- Group 2
Patients aged over 80 years old and without history of atrial fibrillation.
Treatment: Blood taken
- Group 3
Patient with cryptogenic stroke or transient ischemic attack history before the age of 50.
Treatment: Blood taken
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Biological Bank for Studies Related to Atrial Fibrillation and Stroke
- Plain-language title
- Blood bank for studying atrial fibrillation and stroke genesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 17 April 2026